381 related articles for article (PubMed ID: 15945344)
21. Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches.
Frame DG
J Support Oncol; 2010; 8(2 Suppl 1):5-9. PubMed ID: 20629452
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
23. Emerging treatments in chemotherapy-induced nausea and vomiting.
Grunberg SM; Slusher B; Rugo HS
Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
[TBL] [Abstract][Full Text] [Related]
24. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence?
Antonarakis ES; Evans JL; Heard GF; Noonan LM; Pizer BL; Hain RD
Pediatr Blood Cancer; 2004 Nov; 43(6):651-8. PubMed ID: 15390297
[TBL] [Abstract][Full Text] [Related]
25. Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors.
Costa AL; Abreu C; Pacheco TR; Macedo D; Sousa AR; Pulido C; Quintela A; Costa L
Biomed Res Int; 2015; 2015():309601. PubMed ID: 26421283
[TBL] [Abstract][Full Text] [Related]
26. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
Celio L; Denaro A; Agustoni F; Bajetta E
J Support Oncol; 2012; 10(2):65-71. PubMed ID: 22005217
[TBL] [Abstract][Full Text] [Related]
27. Antiemetic guidelines: creating a more practical treatment approach.
Koeller JM; Aapro MS; Gralla RJ; Grunberg SM; Hesketh PJ; Kris MG; Clark-Snow RA
Support Care Cancer; 2002 Oct; 10(7):519-22. PubMed ID: 12324805
[TBL] [Abstract][Full Text] [Related]
28. Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer.
Miller PJ; Balu S; Buchner D; Walker MS; Stepanski EJ; Schwartzberg LS
J Med Econ; 2013 Oct; 16(10):1179-89. PubMed ID: 23919632
[TBL] [Abstract][Full Text] [Related]
29. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
[TBL] [Abstract][Full Text] [Related]
30. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Navari RM
Future Oncol; 2010 Jul; 6(7):1073-84. PubMed ID: 20624119
[TBL] [Abstract][Full Text] [Related]
31. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
[TBL] [Abstract][Full Text] [Related]
32. Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Oddby-Muhrbeck E; Öbrink E; Eksborg S; Rotstein S; Lönnqvist PA
Acta Anaesthesiol Scand; 2013 Jul; 57(6):749-53. PubMed ID: 23281590
[TBL] [Abstract][Full Text] [Related]
33. Management of chemotherapy-induced nausea and vomiting.
Van Ryckeghem F; Van Belle S
Acta Clin Belg; 2010; 65(5):305-10. PubMed ID: 21128556
[TBL] [Abstract][Full Text] [Related]
34. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.
Antonarakis ES; Hain RD
Arch Dis Child; 2004 Sep; 89(9):877-80. PubMed ID: 15321871
[TBL] [Abstract][Full Text] [Related]
35. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
36. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy.
Chan A; Tan SH; Low XH; Yap KY
Nurs Res; 2012; 61(6):405-12. PubMed ID: 22960588
[TBL] [Abstract][Full Text] [Related]
37. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
Oo TH; Hesketh PJ
Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
[TBL] [Abstract][Full Text] [Related]
38. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.
Bleicher J; Bhaskara A; Huyck T; Constantino S; Bardia A; Loprinzi CL; Silberstein PT
J Support Oncol; 2008 Jan; 6(1):27-32. PubMed ID: 18257398
[TBL] [Abstract][Full Text] [Related]
39. Comparative activity of antiemetic drugs.
Jordan K; Schmoll HJ; Aapro MS
Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
[TBL] [Abstract][Full Text] [Related]
40. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]